Company Press Release
Apomorphine: The Rediscovery of an Old Treatment for Parkinson's
Disease? - Volunteers Sought for Minneapolis Neuroscience Institute
Study
MINNEAPOLIS, Sept. 27, 1999 /PRNewswire/ -- Paul Tuite, M.D., of Abbott
Northwestern Hospital's Minneapolis Neuroscience Institute, is part of a
national team of physicians studying the safety and effectiveness of
apomorphine, an investigational medication to control motor fluctuations
or varying movements of the arms or legs associated with Parkinson's
disease.
During the course of the study, examinations, lab tests, evaluations
required by the study and medication or placebo will be provided at no
cost. At the end of the study, participants may be eligible to receive
apomorphine for an additional six months.
Apomorphine was discovered in 1869, when doctors combined acid with
morphine. The result did not relieve pain nor was it addictive. It was
rediscovered in the 1970s and since that time, doctors in France and
Britain developed apomorphine tablets that are placed under the tongue.
Apomorphine is currently used to treat people with Parkinson's disease
in Canada and Europe. It is taken in addition to other anti-parkinsonian
medications, such as L-dopa (Sinemet).
Study participants must have Parkinson's disease, be between the ages 31
and 75, taking three or more doses of L-dopa (Sinemet) per day, and
experience one or more periods of immobility or motor fluctuations per
day. The study will require ten visits over 18 weeks. For more
information or to participate, call Mary Dargay Richards at
612-863-3200.
Abbott Northwestern Hospital is part of Allina Hospitals & Clinics, a
non-profit network of hospitals, clinics and other health care services.
Allina Hospitals & Clinics provides care throughout Minnesota and
western Wisconsin.
SOURCE: Allina Health System
Copyright © 1999 PRNewswire.
--
Judith Richards, London, Ontario, Canada
[log in to unmask]
^^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
`````
